Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with heart failure (HF) and type 2 diabetes. Their effect in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS), however, remains unclear. This study evaluated whether SGLT2 inhibitors reduce all-cause mortality and HF hospitalisations after TAVR.

Methods

A systematic search of PubMed, ScienceDirect, Cochrane (CENTRAL), Scopus and Embase was performed through April 2025 for studies comparing post-TAVR outcomes between SGLT2 inhibitor users and non-users. Outcomes of interest included a composite of all-cause mortality or heart failure (HF) hospitalisation, along with the individual components of all-cause mortality and H

SUBMITTER: Daniyal SM 

PROVIDER: S-EPMC12942055 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature